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Abstract
Background: There is no evidence-based guidance to facilitate design decisions for confirmatory trials or
systematic reviews investigating treatment efficacy for adults with tinnitus. This systematic review therefore seeks to
ascertain the current status of trial designs by identifying and evaluating the reporting of outcome domains and
instruments in the treatment of adults with tinnitus.
Methods: Records were identified by searching PubMed, EMBASE CINAHL, EBSCO, and CENTRAL clinical trial
registries (ClinicalTrials.gov, ISRCTN, ICTRP) and the Cochrane Database of Systematic Reviews. Eligible records were
those published from 1 July 2006 to 12 March 2015. Included studies were those reporting adults aged 18 years or
older who reported tinnitus as a primary complaint, and who were enrolled into a randomised controlled trial, a
before and after study, a non-randomised controlled trial, a case-controlled study or a cohort study, and written in
English. Studies with fewer than 20 participants were excluded.
Results: Two hundred and twenty-eight studies were included. Thirty-five different primary outcome domains were
identified spanning seven categories (tinnitus percept, impact of tinnitus, co-occurring complaints, quality of life,
body structures and function, treatment-related outcomes and unclear or not specified). Over half the studies
(55 %) did not clearly define the complaint of interest. Tinnitus loudness was the domain most often reported
(14 %), followed by tinnitus distress (7 %). Seventy-eight different primary outcome instruments were identified.
Instruments assessing multiple attributes of the impact of tinnitus were most common (34 %). Overall, 24 different
patient-reported tools were used, predominantly the Tinnitus Handicap Inventory (15 %). Loudness was measured
in diverse ways including a numerical rating scale (8 %), loudness matching (4 %), minimum masking level (1 %)
and loudness discomfort level (1 %). Ten percent of studies did not clearly report the instrument used.
Conclusions: Our findings indicate poor appreciation of the basic principles of good trial design, particularly the
importance of specifying what aspect of therapeutic benefit is the main outcome. No single outcome was reported
in all studies and there was a broad diversity of outcome instruments.
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Background
Tinnitus is an auditory percept – often described as a
‘ringing in the ears’– in the absence of a corresponding
auditory stimulus and is experienced by approximately
10–20 % of the population [1]. As a symptom there is a
no consensus on its aetiology [2, 3] and work is ongoing
to profile tinnitus so that interventions can be more spe-
cifically targeted [4]. For a subset of individuals, tinnitus
severely interferes with activities of daily life, but its im-
pact is wide-ranging and heterogeneous across individuals.
Patients report problems in getting to sleep, the need to
avoid noisy situations, hearing difficulties, difficulties with
concentration, and experience despair, frustration, irrita-
tion, depression, fear and worry [5]. Currently, no cure ex-
ists for tinnitus but many interventions are being tested
[6]. There is reasonable evidence to suggest that cognitive
behavioural-based psychological treatments are effective
at improving quality of life [7], negative mood, dysfunc-
tional beliefs and tinnitus-related fear [8].
Despite some optimism for treating tinnitus-related
distress [9] the field is plagued by a number of funda-
mental and recurring problems that limit the evidence
base and ultimately affect patient care and policy-related
decisions. From a trialists’ perspective there is disagree-
ment on what tinnitus-related problems constitute dis-
tinct elements of tinnitus, such as perceived loudness or
emotional distress, and which are sufficiently important
to be considered as domains that should be measured in
all studies [10]. This situation has contributed to the
high level of diversity in, for example, trial design and
measurement of outcomes in confirmatory randomised
controlled trials, which hinders comparison and meta-
analysis across studies [6]. A recent systematic review ex-
amined outcomes of randomised controlled trials of inter-
ventions for adults with tinnitus up to March 2013 [11].
However, the review was not concerned with evaluating
what was measured, nor the choice of outcome instru-
ments. Rather, it focused on evidence for treatment-related
benefits and harms, using this information to develop a
clinical practice guideline [12]. Hence, further investigation
is warranted to determine more generally what outcomes
(namely domains and instruments) are being used in trials
of tinnitus interventions.
The difficulties in synthesising evidence from tinnitus tri-
als has negative implications for the provision of effective
clinical care since clinicians, insurers, healthcare commis-
sioners, regulatory bodies and other policymakers cannot
make informed decisions without good evidence. There are
very few practice guidelines and so in the UK and other
countries care is not delivered to tinnitus patients in a
standardised way [13]. Rather it tends to be driven by reim-
bursement policies and by which clinical profession
(general practitioner, ENT specialist, audiologist, clinical
psychologist, etc.) delivers the care.
In sum, the variations in research and in clinical meth-
odologies used to assess, treat, and study tinnitus form a
problematic circle, where an incomplete evidence base
means that clinical guidelines are developed with limited
knowledge, and the lack of standardised clinical practices
cannot reliably feed back into addressing important
research questions. This scenario is ultimately likely to
contribute to an inefficient use of scarce healthcare re-
sources and unnecessary suffering for patients. At
present we attempt to break this circle by examining
what outcome domains have been defined, and what
outcome measures have been used in studies of treat-
ments for adults with tinnitus, by means of a systematic
review of publicly available trial protocols. This should
ultimately lead to a description of a minimum standard
for trialists to choose outcome measures for use in clin-
ical trials that evaluate a tinnitus intervention [10]. A
core set would enable results to be more easily com-
pared and synthesised and the most effective interven-
tions to be identified [14].
Objectives
The primary objective of this systematic review is to
identify and evaluate the current reported outcome do-
mains in clinical and experimental studies of adults with
tinnitus, with a focus on trial designs investigating the
treatment of tinnitus, and published between the date of
an international consensus meeting in July 2006 [15]
and March 2015. Data collection considered both which
domain of tinnitus was identified as important for dem-
onstrating therapeutic benefit and which instrument was
used to assess that domain. Three secondary objectives
considered the choice of instruments with respect to
identifying patterns: (1) across continents to determine
whether there are geographical preferences for using one
primary outcome instrument over another, (2) across
years to determine changes over time in the uptake of
outcome instruments as a primary outcome, and (3)
across interventions to determine whether particular
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classes of intervention favour using one primary out-
come instrument over another.
Methods
Details of the study eligibility criteria, information sources,
search strategy, selection and data collection processes, as
well as data synthesis methods were published as a protocol
in advance of completing the data collection [16]. Reporting
is guided by the Preferred Reporting Items for Systematic
reviews and Meta-analyses (PRISMA) [17] and are de-
scribed using the PRISMA checklist (see Additional file 1).
Eligibility criteria
Study eligibility was defined according to PICOS (Patient,
Intervention, Comparison, Outcome, Setting) and there
were no modifications to the published protocol [16]. All
included studies assessed adults (men and women) aged
18 years or older who reported tinnitus as one of their pri-
mary complaints, irrespective of whether they were re-
cruited from clinical or non-clinical populations. There
were no restrictions on the type of intervention as long as
the main motivation was to bring about a therapeutic bene-
fit for people with tinnitus. Studies in which the impact on
tinnitus was of secondary relevance (e.g. where reducing
hearing problems was the primary aim) were excluded.
Consistent with this approach, only those studies reporting
tinnitus-related changes as a primary outcome were in-
cluded, irrespective of how those changes were measured.
The systematic review included randomised controlled
trials, before and after studies, non-randomised controlled
trials, case-controlled studies and cohort studies. There
were no restrictions on research settings.
To be included in this report, articles were required to
be written in English and published in or after July 2006
[15]. These decisions were motivated by resource limita-
tions. Furthermore, to improve clinical and scientific
value, any studies either recruiting fewer than 20 partici-
pants with tinnitus or having fewer than 20 at the end
point of the study were excluded. This cut-off was selected
in advance, following Needleman et al. [18]. We included
published systematic reviews and meta-analyses that con-
sidered tinnitus trials meeting the above criteria. These re-
views and meta-analyses were not subject to the data
collection process itself, but we did a hand-search and in-
clude any additional eligible studies reported within them.
During the data collection process, a small number of
studies were identified where age-related eligibility or target
sample size were missing. In cases where neither pieces of
information were reported, the corresponding author was
contacted for more details by email, with one reminder.
Information sources
Studies were identified by searching electronic databases
of research literature (Table 1). The following list details
the database, as well as the number of records identified by
the search strategy (in parentheses): PubMed (National
Centre for Biotechnology Information) (n = 759), EMBASE
(Ovid) (n = 244), Cumulative Index to Nursing and Allied
Health Literature (CINAHL, EBSCO) (n = 145) and the
Cochrane Central Register of Controlled Trials (CEN-
TRAL) (n = 560). A number of different electronic trial
registers were also searched: ClinicalTrials.gov (n = 141),
the International Standard Randomised Controlled Trial
Number registry (ISRCTN, BioMed Central) (n = 22), the
International Clinical Trials Registry Platform (ICTRP,
World Health Organisation) (n = 183), and the Cochrane
Database of Systematic Reviews (CDSR) (n = 23). Electronic
searches were run on 12 and 13 March 2015 by authors
DAH and AJS, and were not updated.
In addition, a hand-search was conducted using the 251
published records that had met eligibility at the abstracts
and full-text screening stages. Specifically, we hand-
searched the set of registered clinical trials to identify any
further registers of the same trial and also to identify any
published protocols or study findings that were indexed to
that trial by its unique study identifier. We also manually
searched the 18 systematic review articles to look for any
overlooked studies for inclusion. An additional 52 records
were identified by these approaches. Following this step,
the systematic review articles themselves were not in-
cluded for data collection purposes.
Search strategy
The search strategy used in this systematic review was
previously published [16]. Search terms for PubMed,
EMBASE, and CINAHL were informed by the PICOS
criteria and were: (1) tinnitus AND (2) stud* OR clinical
trial* OR therap* OR treatment* OR intervention*.
Where possible the search was limited to humans (not
animals), adults (not paediatric), English language and
2006-date of search. The syntax for the subsequent
search of the CENTRAL trials registry of the Cochrane
Collaboration was: #1 tinnitus; #2 Paediatric:TI,AB,KY;
#3 Pediatric:TI,AB,KY; #4 child*:TI,AB,KY; #5 #1 NOT
Table 1 Table summarising the electronic information sources
used. For a description of the abbreviations, see text
Type of electronic search Database Number of items (n)
Academic databases PubMed 759
EMBASE 244
CINAHL 145
CENTRAL 560
Clinical trial registers ClinicalTrials.gov 141
ISRCTN 22
ICTRP 183
CDSR 23
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#2 NOT #3 NOT #4, #6 english:LA, #7 #5 AND #6, #8
(2006–2015):PD NOT IN MEDLINE NOT IN EMBASE
AND 2006 TO 2015:YR, and #9 #5 NOT INMEDLINE
NOT INEMBASE. Electronic trial registers all used ‘tin-
nitus’ as the main search term.
Data management
DAH was responsible for data management and main-
tained the editorial rights. All identified records were
saved into a Microsoft Excel master file where records
were tracked through the screening and data collection
process by a unique study identification code. A simple
system of record annotation was implemented to cap-
ture reasons for exclusion. At the end of data collection,
checking and formatting, a pdf copy of the master file
was created as a ‘locked’ record so that there is a version
of the data that cannot be edited in error (7 December
2015). An editable Excel version of this document can
be downloaded (see Additional file 2).
Selection process
Endnote was used to remove 141 duplicate records from
the PubMed, EMBASE and CINAHL searches, while the
remaining 362 duplicates were manually identified
within the Excel master file by DAH and HH using au-
thor names, study title and trial registration number.
This gave a total of 1574 records for eligibility screening.
Screening steps were carried out DAH, HH and AJS.
Following the pre-specified protocol, a two-step process
was implemented to decide eligibility: first by reading
the title, and second by reading the abstract and full text.
It was possible to exclude 1153 records by title and sum-
mary information alone (see Fig. 1). Full texts were ob-
tained for the 421 remaining records that potentially
met the inclusion criteria or for which there was
insufficient summary information to make a clear deci-
sion. From this step, a further 170 records were ex-
cluded, leaving 251 for data extraction. It is interesting
to note that almost one third of those records excluded
at this step was due to the small sample size of the study
(see Fig. 1). Twenty-two records were excluded because
they recruited participants below 18 years of age. More-
over, 55 full texts were excluded because the sample size
was less than 20 participants and 11 full texts were ex-
cluded because they were not available in English. In-
stead, these were published in national journals written
in the native language. So that the reader can scrutinise
the data for evidence of geographical bias in these three
full-text exclusion criteria, details are broken down by
country in Table 2. This information gives some indica-
tion for a risk of bias excluding tinnitus studies con-
ducted in the USA since 21 were removed on the basis
of small sample size, leaving only 39 records from the
USA contributing to the systematic review. There is also
a risk of bias excluding tinnitus studies conducted in
China since six were removed because they were pub-
lished in Chinese, leaving only three records from China
contributing to the systematic review. Note that lan-
guage bias was avoided for studies registered on
ISRCTN and ICTRP since an English language transla-
tion is given. Ten trials in Iran, seven in Japan and two
in China, two in Brazil and one in the Republic of Korea
were included via this route.
At least two co-authors performed each key step (i.e.
title screening, full-text screening, and data collection) in-
dependently for every record. Due to an error in allocating
full texts to co-authors, some records had data collection
by more than two co-authors (31 were completed by three
co-authors, 11 by four and 9 by five). Discrepancies be-
tween independent co-authors were rare and were mostly
Fig. 1 Flow diagram of study records
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accountable by differences in terminology. These were re-
solved by DAH who was responsible for data manage-
ment. As per the protocol [16], inter-rater agreement was
not calculated, but all co-authors reviewed and approved
the master file before data lock.
We pieced together data from multiple reports of the
same study by manually screening all included records
using author names, study title and trial registration
number. This step of consolidating records happened
throughout the data collection process, and in particular
during the data formatting check. Where there were
multiple reports, the data extraction reflects the infor-
mation provided in the report with the latest publication
date. Any discrepancies between information reported in
the different articles were noted under the data item
heading ‘intention versus reporting’.
Data collection process
We contacted 29 trialists to request missing information
about the minimum age for inclusion and two investigators
to request missing information about sample size. With re-
spect to age, 20 confirmed that all participants were 18 years
of age or older, two authors could no longer be contacted,
two responded but were unable to confirm the minimum
age, one responded but said he was too busy to provide the
information, and four did not respond. On the basis of this,
nine records were excluded. Both investigators who were
contacted about sample size were able to provide the re-
quired information and so these records were included. A
summary of those relevant records are provided in more
detail in an additional Table (see Additional file 3). After ex-
clusion, 228 records were included for data collection. A
further Table provides full references (see Additional file 4).
Data items gave rise to headings in a data collection
sheet. Data collection was guided by an electronic form
(Excel spreadsheet) that was also used to collate all re-
sponses. Data collection was conducted by a pool of 20
project team members (number of extracted studies
ranged from 5 to 228, median 19.5). The primary reason
for not limiting data collection to a smaller pool was to
Table 2 Summary of those records excluded at the full-text screening stage because (1) the sample size was less than 20 participants,
(2) because the articles were not available in English, or (3) they recruited participants below 18 years of age. Details are broken down by
country
Sample size <20 Non- English language Minimum eligibility (age in years)
13 14 15 16 17
Austria 1 1
Belgium 2 1
Czech Republic
Finland 2
France 3
Germany 4 1 2 4
Italy 3 1
Spain 1
Sweden 3
Switzerland 1 1
The Netherlands 3
Turkey 1
Iran 2 1
Iraq 1
Israel 1
Egypt 1
Brazil 2 1 1
Uruguay 1
China 6 1 1
Japan 3
Republic of Korea 1 1 1 1
Australia 2 1
New Zealand 1 1
USA/Canada 22
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lessen the resource burden since we received no grant
funding to conduct the research activity. To mitigate
against observer bias, a full set of guidance notes was pro-
duced for the data collection procedure and calibration
exercises were conducted with new members of the re-
view team prior to any individual contribution to this re-
view. Both the sheet and the guidance notes were
developed and revised across several review authors dur-
ing a 3-day workshop and through two iterations of pilot-
ing. Data collection was conducted independently and
with at least two team members for every included record.
In an amendment to the pre-specified protocol, DAH veri-
fied the data collection for all included records to ensure
consistency in approach and in terminology; the latter be-
ing necessary for automated data counting. Another step
to mitigate against observer bias during the data collection
process was by avoiding any instance where an individual
extracted data relating to one of their own trials.
Data items
Data items included all of the fields reported in the pub-
lished protocol [16]. A majority of data items fall within the
PICOS framework. Participant data items relating to the
inclusion criteria for each trial record were: (1) minimum
age, (2) maximum age (if any), (3) tinnitus duration, (4)
intermittent or constant tinnitus, (5) pulsatile or non-
pulsatile tinnitus, (6) tinnitus severity, (7) any other sub-
types of tinnitus, and (8) any other health-related comor-
bidities. Participant data items relating to the exclusion
criteria for each trial record were: (9) any other subtypes of
tinnitus, and (10) health-related comorbidities. Intervention
data items recorded the (11) type and (12) duration of
intervention in each arm of the trial. Data items describing
the study design (i.e. ‘comparison’) comprised: (1) a pull-
down list of study design options (randomised controlled
trials, before and after studies, non-randomised controlled
trials or case-control studies and cohort studies) and (2) a
record of the duration of each intervention, separately for
each arm of the trial. Outcome data items were: (1) the out-
come domain(s) specified by the investigators, (2) the in-
struments specified by the investigators, and (3) time
frame. Information relating to these three data items was
recorded separately for all primary and secondary out-
comes. Where authors were not explicit about this distinc-
tion, we tried to tease this information out of the article by
reading the Methods and Results sections of each record.
But if this was not possible, then all information was en-
tered as a primary data item. A ‘setting’ data item reported
the country where the study was conducted. Supplementary
information was also extracted from each included trial on:
(1) the name and email address of the corresponding
author, (2) the date of study start, (3) the aim of the trial,
(4) sample size calculation, with a full-text extraction of the
reported details, (5) the sample size, (6) a description of any
modifications to the methods, particularly any discrepancies
between the trial protocol and the subsequent report of the
findings, and (7) the date of publication. The protocol was
amended so that if minimum age of eligibility or sample
size estimate was not reported, then the data collection re-
corded the minimum age of the recruited participants or
the recruited sample size as the ‘next best alternative’, where
this information was given. An additional data item not
planned in the protocol recorded whether the study authors
specified any minimal clinically important difference, or re-
lated construct that was used to interpret the clinical sig-
nificance of the findings. For example, Cima and et al. [8]
specified a pre- versus post-intervention change of 0.065
(SD 0.15) in health utility score measured using the 36-item
short form Health Survey. This information is not reported
here, but will be presented in a separate manuscript. If any
information is not reported, then ‘not stated’ was recorded
in the corresponding field.
Where a trial record consolidated several pieces of in-
formation (such as a protocol and the published find-
ings), the data items reported in the synthesis related to
the most recent publication. For those records in which
several pieces of information are consolidated into a sin-
gle record, we sought to detect any modifications to the
methods leading to inconsistencies between the protocol
and the final reported study. Given that the review fo-
cused on the design of clinical trials, wherever possible
information relating to each data item was taken from
the study design reported in the most recent publication,
not from any report of the study results. For example,
sample size recorded the estimated sample size not the
number of participants actually enrolled into each inter-
vention arm. And, the date of publication recorded the
date of the print copy, not the date of first submission,
acceptance or the date of 'online first' publication.
Outcomes and prioritisation
The primary research question in this review concerned
the outcome domains (and instruments) being used in
clinical trials of tinnitus treatment. Therefore, the prior-
ity for data synthesis and reporting of findings was data
relating to all primary outcomes. Where authors failed
to distinguish between primary and secondary outcomes,
we classified them all as primary. Those outcomes expli-
citly defined as secondary were also examined, but as a
secondary research question.
Risk of bias in individual studies
Given that the primary objective of this systematic re-
view concerns methodology (not therapeutic effects), we
limited the assessment of risk of bias to the data collec-
tion methods for consolidated records rather than any
analysis of those data. In particular, we investigated
where there were inconsistencies between the outcomes
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defined in the trial registration and/or protocol and
those given in the subsequent study report. Of the 228
studies selected for inclusion, 60 (26 %) had multiple re-
cords. We examined only those consolidated records with
a protocol and study report(s) comparing data items
across records. From this set, 21 were found to have de-
scriptions of eligibility criteria (inclusion or exclusion),
primary outcome measures, and/or secondary outcome
measures that were altered retrospectively in the final re-
port. An additional Table gives more details about the
findings from the risk of bias assessment (see Additional
file 5). None of the studies reported a justification for the
changes, but insufficient information was given in the
publications to determine any instances of intentional de-
ception (i.e. outcome-reporting bias) where outcomes had
been selected on the basis of the results, for inclusion in
the publication of trial findings [19–21]. We did not con-
tact authors to examine reasons for altered reporting.
Results
The primary objective was to identify and evaluate the
current reported outcome domains and instruments in
designs of intervention studies of adults with tinnitus,
published since July 2006.
Domains
For the first part of the analysis, we scrutinised the data
collected under the data item relating to the primary
outcome domain(s) specified by each set of investigators.
There were 505 data entries describing 35 different types
of primary domain (Table 3). Domain grouping was
conducted by a subgroup of tinnitus experts (three ENT
surgeons, one audio-vestibular physician, and two re-
searchers) and was broadly informed by the Cochrane
Effective Practice and Organization of Care (EPOC) rec-
ommendations [22]. Patient outcomes concerned with
health status, well-being and health behaviours consti-
tuted the largest category by far and so we expanded this
into domains relating to (1) the tinnitus percept, (2) the
impact of tinnitus, (3) other co-occurring complaints,
(4) health-related quality of life, and (5) body structures
and functions (Table 3). Remaining EPOC categories
were (6) adverse events or harms and (7) satisfaction,
with further categories for (8) treatment-related out-
comes, and (9) for domains that were unclear or not
specified by the author. The most popular primary out-
come domain directly relating to tinnitus was ‘tinnitus
loudness’ (n = 70, 14 % defined as primary outcome do-
main in all studies), with ‘tinnitus distress’ (n = 33, 7 %)
and ‘tinnitus annoyance’ (n = 21, 4 %) following.
Over half (n = 279, 55 %) of the data entries did not
clearly describe the complaint of interest. Since this was
such a large percentage, we chose to examine this in
more detail rather than simply report as a quantitative
summary of quality, as per the protocol [16]. Instead, we
sought to describe the ways in which the authors’ speci-
fication of each primary outcome domain appeared to be
inadequate using a narrative approach. Primary outcome
domains in category 7 were classified into five subheadings
(Table 3). On 128 occasions (25 %), the investigators did
not explicitly state which domain their trial intended to as-
sess and so we refer to these as ‘not specified’. ‘Tinnitus se-
verity’ was the next most common phrase used to define
the outcome domain of interest (n = 69, 14 %). We note
that in our protocol [16], we had stated that this is not an
adequate domain because it does not explain the dimension
of complaint on which severity should be considered. The
same applies to ‘tinnitus handicap’ (n = 14, 3 %). We also
experienced difficulty in interpreting a further 58 (12 %)
data entries because the terminology was indeterminate (re-
ferred to as ‘cannot code’). We are confident that this is not
a coding issue, as DAH verified that the data collection for
all included records captured the text as reported by the au-
thors. Examples include ‘improvement’, ‘treatment re-
sponder’, ‘change’, ‘tinnitus impact’, ‘size of tinnitus problem’,
‘tinnitus impairment’, ‘problems associated with tinnitus’, ‘dif-
ficulties due to tinnitus’, ‘degree of tinnitus’, ‘sensation of tin-
nitus’, and ‘tinnitus characteristics’. Again, none of these
clearly explain the dimension of complaint on which im-
provement or problems should be considered. ‘Multi-do-
main specification’ refers to composite measures describing
several different complaints such as ‘tinnitus annoyance
and distress’ and ‘internal thoughts, sensations and feelings’
(n = 10, 2 %).
There were 579 data entries describing 60 different types
of secondary domain. Again, Table 3 indicates similar pat-
terns, with ‘tinnitus loudness’ (n = 42, 7 %), with ‘tinnitus
distress’ (n = 18, 3 %) and ‘tinnitus annoyance’ (n = 15, 3 %)
being the most popular. Safety (n = 43, 7 %), Quality of life
(n = 20, 3 %), and depression (n = 18, 3 %) were also popu-
lar as secondary outcome domains.
Instruments
The second part of the primary objective was to identify
and evaluate the current reported outcome instruments
and for this we interrogated the data collected under the
data item relating to the primary outcome instrument(s)
specified by each set of investigators. Overall, there were
505 data entries describing 78 different types of instrument
(Table 4). We used a categorisation scheme based on the
one for domains. Instruments were grouped according to
whether the tests relate to: (1a) the tinnitus percept (investi-
gator-administered), (1b) the tinnitus percept (numerical
rating scale), (2a) the impact of tinnitus (patient-reported
questionnaire), (2b) the impact of tinnitus (numerical rating
scale), (3) other co-occurring complaints, (4a) health-
related quality of life (patient-reported questionnaire), (4b)
health-related quality of life (numerical rating scale), (5)
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Table 3 Summary of all primary and secondary outcome domains across all 228 clinical trials. Domains have been grouped according
to eight major topic categories. Categories 1–5 relate to different types of ‘patient outcomes’, categories 6–7 relate to ‘adverse events’
and ‘satisfaction’, following the Effective Practice and Organisation of Care classification scheme [22]. Categories 8 and 9 best describe
the remaining outcomes reported in the included records. Percentages are rounded so, for example, 0 % denotes a value that is <0.5 %
Primary domains Secondary domains
Number Percentage (%) Number Percentage (%)
(1) Domains relating to the tinnitus percept:
Tinnitus loudness 70 14 % 42 7 %
Tinnitus pitch 12 2 % 13 2 %
(2) Domains relating to the impact of tinnitus:
Tinnitus distress 33 7 % 18 3 %
Tinnitus annoyance 22 4 % 15 3 %
Tinnitus awareness 10 2 % 2 0 %
Cognition 2 0 % 4 1 %
Behaviour 1 0 % 0 -
Acceptance of tinnitus 0 - 3 1 %
Catastrophising 0 - 1 0 %
Concentration 0 - 2 0 %
Tinnitus intrusiveness 0 - 2 0 %
Tinnitus-related cognitions 0 - 1 0 %
Tinnitus-related fear 0 - 1 0 %
(3) Other co-occurring complaints:
Depression 8 2 % 18 3 %
General distress 5 1 % 5 1 %
Anxiety 4 1 % 6 1 %
Anxiety and depression 4 1 % 13 2 %
Hearing threshold 4 1 % 11 2 %
Hearing loss 2 0 % 1 0 %
Speech perception 2 0 % 0 -
Hearing handicap 1 0 % 3 1 %
Hearing loss annoyance 1 0 % 0 -
Sleep quality 1 0 % 12 2 %
Somatic sensations 1 0 % 1 0 %
Fear (anxiety) 0 - 1 0 %
Hyperacusis 0 - 3 1 %
Mood 0 - 2 0 %
Sound tolerance 0 - 1 0 %
Speech discrimination 0 - 3 1 %
(4) Health-related quality of life (QoL):
QoL (tinnitus) 16 3 % 13 2 %
QoL 9 2 % 20 3 %
Coping 3 1 % 0 -
Occupational health 0 - 1 0 %
QoL (hearing) 0 - 1 0 %
Sense of control 0 - 1 0 %
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body structures and functions, (6) adverse events or harms,
(7) satisfaction, (8) treatment-related outcomes, or (9) were
unclear or not specified by the authors. Twenty-eight differ-
ent instruments were used only once as a primary outcome
and these are listed in an additional Table (see Additional
file 6).
Instruments assessing the impact of tinnitus were
most common and of these, the Tinnitus Handicap
Table 3 Summary of all primary and secondary outcome domains across all 228 clinical trials. Domains have been grouped according
to eight major topic categories. Categories 1–5 relate to different types of ‘patient outcomes’, categories 6–7 relate to ‘adverse events’
and ‘satisfaction’, following the Effective Practice and Organisation of Care classification scheme [22]. Categories 8 and 9 best describe
the remaining outcomes reported in the included records. Percentages are rounded so, for example, 0 % denotes a value that is <0.5 %
(Continued)
(5) Body structures and functions:
Neck mobility 1 0 % 1 0 %
Neural activity 1 0 % 2 0 %
Oxidative stress 1 0 % 0 -
Active myofascial
trigger points
0 - 1 0 %
Blood parameters 0 - 1 0 %
Gene expression 0 - 1 0 %
Metabolism 0 - 4 1 %
Neck pain 0 - 1 0 %
Neuroendocrine hormones 0 - 1 0 %
Pharmacokinetics 0 - 1 0 %
Structural brain change 0 - 1 0 %
(6) Adverse events or harms:
Safety and tolerability 6 1 % 4 1 %
Safety 2 0 % 43 7 %
Drug safety and tolerability 1 0 % 4 1 %
Side effects 1 0 % 15 3 %
Headache 0 - 1 0 %
Pain frequency 0 - 1 0 %
Pain intensity 0 - 1 0 %
(7) Satisfaction:
Treatment satisfaction 1 0 % 5 1 %
(8) Treatment-related outcomes:
Withdrawals 1 0 % 0 -
Adequacy of blinding 0 - 1 0 %
Credibility (sham) 0 - 1 0 %
Credibility (treatment) 0 - 2 0 %
Needling sensation (acupuncture) 0 - 1 0 %
Therapeutic alliance 0 - 1 0 %
Tolerability 0 - 5 1 %
(9) Domain of interest unclear or not specified by the authors:
Not specified 128 25 % 140 24 %
Cannot code 58 11 % 76 13 %
Multi-domain specification 10 2 % 10 2 %
Tinnitus severity 69 14 % 29 5 %
Tinnitus handicap 14 3 % 5 1 %
Total 505 100 % 579 100 %
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Table 4 Summary of all primary and secondary outcome instruments used across all 228 clinical trials. Instruments have been grouped
according to the major domain categories reported in Table 3, as well as those instruments that were not clearly specified by the authors.
Note that the total refers to the number of instruments across all 228 trials. The remainder are reported in Additional file 6. Percentages are
rounded so, for example, 0 % denotes a value that is <0.5 %
Primary outcome instruments Secondary outcome instruments
Number Percentage (%) Number Percentage (%)
(1a) Investigator-administered tests relating to the tinnitus percept:
Tinnitus loudness matching 20 4 % 16 3 %
Tinnitus pitch matching 9 2 % 22 4 %
Minimum masking level 5 1 % 12 2 %
Loudness discomfort level 3 1 % 2 0 %
Tinnitus bandwidth matching 0 - 2 0 %
(1b) Patient-reported numerical rating scales relating to the tinnitus percept:
Tinnitus loudness 37 8 % 24 4 %
Tinnitus pitch 0 - 2 0 %
(2a) Patient-reported questionnaire instruments relating to the impact of tinnitus:
Tinnitus Handicap Inventory 77 15 % 31 5 %
Tinnitus Questionnaire (German version) 29 6 % 11 2 %
Tinnitus Questionnaire (English version) 5 1 % 0 -
Tinnitus Functional Index 18 4 % 3 1 %
Tinnitus Beeinträchtigungs Fragebogen 13 3 % 8 1 %
Tinnitus Severity Index 12 2 % 1 0 %
Tinnitus Reaction Questionnaire 11 2 % 2 0 %
Tinnitus Handicap Questionnaire 8 2 % 5 1 %
Mini-Tinnitus Questionnaire 6 1 % 0 -
Tinnitus Effects Questionnaire 2 0 % 0 -
Tinnitus diary 2 0 % 0 -
Tinnitus Psychological Impact Questionnaire 2 0 % 0 -
Tinnitus Severity Scale 0 - 6 1 %
Tinnitus Acceptance Questionnaire 0 - 6 1 %
(2b) Patient-reported numerical rating scales relating to the impact of tinnitus:
Tinnitus distress 7 2 % 8 1 %
Tinnitus annoyance 21 4 % 14 2 %
Tinnitus awareness 10 2 % 2 0 %
(3) Patient-reported questionnaire instruments relating to other co-occurring complaints:
Beck Depression Inventory 7 1 % 13 2 %
Hospital Anxiety and Depression Scale 7 1 % 27 5 %
Perceived Stress Questionnaire 3 1 % 0 -
Spielberger State and Trait Anxiety Inventory 3 1 % 3 1 %
Brief-Coping with Problems Experienced 2 0 % 0 -
Pittsburgh Sleep Quality Index 2 0 % 2 0 %
Hearing Handicap Inventory 1 0 % 4 1 %
Hyperacusis questionnaire (undefined) 1 0 % 2 0 %
Attention and Performance Self-assessment Scale 0 - 2 0 %
Befindlichkeitsskala 0 - 2 0 %
Cognitive Failures Questionnaire 0 - 2 0 %
Depression Anxiety and Stress Scale 0 - 3 1 %
Hall et al. Trials  (2016) 17:270 Page 10 of 19
Inventory was the most popular (n = 77, 15 %) [23] and
was one of the instruments recommended by the 2006 con-
sensus meeting [15]. Other recommended questionnaires
were the Tinnitus Questionnaire (n = 34, 7 %), the Tinnitus
Reaction Questionnaire (n = 11, 2 %), and the Tinnitus
Handicap Questionnaire (n = 8, 2 %). However, our review
Table 4 Summary of all primary and secondary outcome instruments used across all 228 clinical trials. Instruments have been grouped
according to the major domain categories reported in Table 3, as well as those instruments that were not clearly specified by the authors.
Note that the total refers to the number of instruments across all 228 trials. The remainder are reported in Additional file 6. Percentages are
rounded so, for example, 0 % denotes a value that is <0.5 % (Continued)
Insomnia Severity Index 0 - 7 1 %
Major Depression Inventory 0 - 5 1 %
Sleep Questionnaire (undefined) 0 - 3 1 %
(4a) Patient-reported questionnaire instruments relating to health-related quality of life:
Clinical Global Impression Scale 4 1 % 14 2 %
36-item short form Health Survey 2 0 % 6 1 %
WHOQOL-BREF 0 - 10 2 %
EuroQoL 0 - 2 0 %
Quality of Life Inventory 0 - 2 0 %
(4b) Patient-reported numerical rating scales relating to health-related quality of life:
Quality of Life (tinnitus) 5 1 % 6 1 %
Quality of Life 4 1 % 1 0 %
(5) Technical and laboratory measurements relating to body structures and functions:
Pure tone audiometry 15 3 % 23 4 %
Speech audiometry (various types) 6 1 % 11 2 %
Electroencephalography 4 1 % 5 1 %
Blood chemistry 2 0 % 10 2 %
Positron Emission Tomography 2 0 % 0 -
Electrocardiogram 1 0 % 4 1 %
Digit symbol test 1 0 % 2 0 %
Blood drug levels 0 - 4 1 %
Magnetic Resonance Imaging 0 - 3 1 %
Otological examination 0 - 4 1 %
Otoscopy 0 - 2 0 %
Psychoacoustic assessment (undefined) 0 - 3 1 %
Tympanometry 0 - 2 0 %
Urine analysis 0 - 2 0 %
(6) Measures of adverse events or harms:
Adverse events/Side effects 4 1 % 30 5 %
(7) Measures of satisfaction: No instruments reported
(8) Measurement instruments of treatment-related outcomes:
Withdrawal rate 2 0 % 2 0 %
(9) Measurement of interest unclear or not specified by the authors:
Cannot code 20 4 % 52 9 %
Other numerical rating scale (undefined) 18 4 % 29 5 %
Questionnaire (authors’ own) 15 3 % 13 2 %
Numerical rating scale of tinnitus severity 12 2 % 1 0 %
Not specified 8 2 % 18 3 %
Total 505 87 % 579 85 %
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indicates that the Tinnitus Functional Index, Tinnitus
Beeinträchtigungs Fragebogen (a shortened version of the
Tinnitus Handicap Inventory translated into German) and
Tinnitus Severity Index were just as widespread.
Tinnitus loudness matching was a popular tool for asses-
sing the tinnitus percept (n = 20, 4 %). A numerical rating
scale of loudness was also a common approach (n = 37,
8 %), but there was little consistency in the measurement
scale used (e.g. Table 5). Other domains relating to the
impact of tinnitus were evaluated using a numerical rating
scale predominantly annoyance (n = 21, 4 %), awareness
(n = 10, 2 %), and distress (n = 7, 1 %). Numerical rating
scales with 0–10 and 0–100 point scales were popular.
About 16 % (n = 78) of the data entries did not clearly
report the instrument used. These were classified into
five subheadings under Table 4, category 9. On 20 occa-
sions (4 %), we experienced difficulty in interpreting the
data entry (referred to as ‘cannot code’). One recurring
example was where investigators did not state the proven-
ance of the ‘tinnitus questionnaire’ which could be either
a published Tinnitus Questionnaire [24, 25], or a transla-
tion of one of these or to an authors’ own instrument. We
observed 15 instances (3 %) where investigators reported
using their own (unpublished) questionnaire, which limits
reproducibility.
There were 579 data entries describing 108 different types
of secondary instrument (Table 4). Of those, 49 instruments
were used only once as a secondary outcome and these are
listed separately in a Table (see Additional file 6). Although
the Tinnitus Handicap Inventory remained a common
choice as a secondary outcome (n = 31, 5 %), other
tinnitus-related questionnaires were much less so. Instead,
adverse events (n = 30, 5 %) and the Hospital Anxiety and
Depression Scale (n = 27, 5 %), pure tone audiometry (n =
23, 4 %), tinnitus pitch matching (n = 22, 4 %), the Clinical
Global Impression Scale (n = 14, 2 %) and the WHOQOL-
BREF (n = 10, 2 %) were some of the more popular choices
for secondary outcomes.
The protocol did state that the timing of the primary
end point would be examined [16], but we did not pursue
this analysis because the timing of the end point was re-
ported inconsistently across studies (some relative to the
start of the treatment and others relative to the end of the
treatment) and the duration of treatment varied so greatly
(some were just a few days, some extended up to 1 year,
and others did not clearly specify). Moreover, the time
frame of surveillance for adverse events was rarely stated.
Pattern of primary outcome instruments across world regions
The first secondary analysis assessed how the pattern of
primary outcome instruments varied across world re-
gions. Countries recruiting into identified clinical trials
were categorised into six world regions using the World
Health Organisation (WHO) as a guide [26]. Findings
are summarised in Fig. 2. The ‘European region’ repre-
sented the greatest research activity with 151 sites
recruiting across all 228 trials. Most research was con-
ducted in Germany (n = 48), Belgium (n = 20), and UK
(n = 12). In the Middle East and Africa region, most tri-
als were conducted in Iran (n = 17), while in Asia most
research was conducted in Japan (n = 11) and the Repub-
lic of Korea (n = 9).
With respect to patient-reported questionnaires relating
to the impact of tinnitus, the Tinnitus Handicap Inventory
was the most common one used as a primary outcome
across all world regions, except for Oceania where the
Tinnitus Reaction Questionnaire was preferred. Since few
clinical trials were conducted in South America or Ocea-
nia, findings for these world regions should be interpreted
with caution. The Tinnitus Questionnaire was common in
Europe, especially in Germany, but not in the rest of the
world. Even in Europe, it is used in different forms
Table 5 Summary of the different formats for numerical rating scales used across all 228 clinical trials. These are used to assess a
wide range of domains including tinnitus loudness annoyance, awareness, distress and tinnitus-related quality of life
Primary outcome instruments Secondary outcome instruments
Number Percentage (%) Number Percentage (%)
Numerical rating scale (0–3) 1 0 % 0 -
Numerical rating scale (0–10) 49 10 % 18 3 %
Numerical rating scale (0–100) 18 4 % 13 2 %
Numerical rating scale (1–9) 0 - 1 0 %
Numerical rating scale (1–10) 12 2 % 0 -
Numerical rating scale (1–100) 1 0 % 0 -
Numerical rating scale (4 points) 3 1 % 2 0 %
Numerical rating scale (5 points) 2 0 % 2 0 %
Numerical rating scale (7 points) 3 1 % 0 -
Numerical rating scale (10 points) 0 - 1 0 %
Numerical rating scale (10-cm line) 5 1 % 14 2 %
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because the English and German versions differ from one
another [28]. The Tinnitus Severity Index was common in
the Middle East and Africa region, but not in other parts
of the world. Measures of tinnitus loudness were also
most common in the Middle East and Africa region (both
using loudness matching and numerical rating scales),
with countries in Asia also favouring a loudness numerical
rating scale.
Pattern of usage of primary outcome instruments across
years
We also examined the status of selected primary outcome
instruments over the time frame of the review (Fig. 3).
Due to the wide variety of instruments, analysis focused
on the most frequently used that were highlighted in the
previous section (Instruments). For meaningful analysis,
we split the total time frame into three periods, using the
best available information. The first period was from 1
January 2011 to 12 March 2015 (i.e. the date of the elec-
tronic searches) (n = 102). The second period was from 1
August 2006 to 31 December 2010 (n = 99). The third
period included any remaining studies in which data was
collected on or before 31 July 2006 (i.e. before the Tin-
nitus Research Initiative (TRI) consensus meeting) [15],
but not published until after this date (n = 27). Here we
describe the patterns for the first two periods because of
the comparable sample size and more robust definition,
but all data are presented in Fig. 3. The Tinnitus Handicap
Inventory, the Tinnitus Handicap Questionnaire, and the
Tinnitus Beeinträchtigungs Fragebogen were equally popu-
lar across both 5-year periods. The Tinnitus Functional
Index and numerical rating scales of tinnitus loudness in-
creased in popularity, while the Tinnitus Questionnaire
(German version), the Tinnitus Reaction Questionnaire,
the Tinnitus Severity Index and tinnitus loudness match-
ing all seemed to decrease in popularity.
Pattern of usage of primary outcome instruments across
interventions
All records were coded according to eight broad classes of
procedure either as part of the intervention of interest or
the control. These were: pharmacology (n = 66), electro-
physiology (n = 59), sound therapy (n = 56), psychological
therapy or counselling (referred to as ‘talking’) (n = 47),
Fig. 2 World map illustrating the distribution of recruiting sites for all included studies, inspired by the World Health Organization (WHO) regional
classification. Figures within each country indicate only one trial [27] had a recruiting site in South Africa and so this was combined with countries in
the WHO Eastern Mediterranean region to create the Middle East and Africa region (n = 20). The WHO Region of the Americas was separated into
North and South America because we anticipated that language differences might influence choice of outcome instruments. Similarly, Australia and
New Zealand were considered separately from Western Pacific region, as Oceania, while other countries were combined with the WHO Southeast Asia
region to create a single Asian region
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complementary therapy (n = 33), surgery (n = 10), manual
physical therapy (n = 7), and relaxation (n = 3). Where in-
terventions involved more than one procedure, all proce-
dures were coded. For example, an intervention involving
an intra-tympanic injection was coded as both pharmacol-
ogy and surgery, and Tinnitus Retraining Therapy with a
Ginkgo biloba supplement was coded as talking, sound
and pharmacology.
The domain of tinnitus loudness was least frequently
assessed in talking therapies (3 %), with the other major
classes of intervention all assessing this perceptual charac-
teristic more frequently: pharmacology (17 %), electrophysi-
ology (16 %), sound therapy (15 %), and complementary
therapy (14 %). In contrast, talking therapies favoured as-
sessments of tinnitus distress (13 %) more than the other
intervention classes: pharmacology (2 %), electrophysiology
(6 %), sound therapy (7 %), and complementary therapy
(4 %). Numerical rating scales and the Tinnitus Handicap
Inventory were commonly used as outcome instruments
for all types of interventions.
Quality assessments
Following the protocol, we assessed the quality of defining
and reporting outcomes in three ways. The first quality as-
sessment considered the degree to which primary outcome
instrument(s) in each study were appropriate and consist-
ent with the authors’ choice of primary outcome domain(s).
For example, the Tinnitus Severity Index would not be con-
sidered an ideal measure for quality of life, nor would ‘psy-
chophysical method’ as a measure of tinnitus loudness.
Within each study, we counted the number of consistent
primary outcomes, calculated as a function of the propor-
tion (%) of primary outcomes in that study. Overall, 31
(14 %) studies achieved a 100 % score, with 16 of those spe-
cifying a single primary outcome. In contrast to this, 133
(58 %) studies scored 0 %, with 52 of those failing to specify
the primary domain and five not specifying the primary
instrument. The remaining studies reported only par-
tially correct outcomes: n = 5 scored 1–25 %, n = 31
scored 26–50 %, n = 21 scored 51–75 % and n = 7
scored 76–99 %.
The second quality assessment demonstrated that few
trial designs were informed by a sample size calculation
based on previous data for the primary outcome instru-
ment. We excluded from this analysis 91 records that
were trial registrations because a sample size calculation
was not required for reporting. Of the remaining 137 re-
cords, sample size calculation was reported in only 37 of
them (27 %). A sample size calculation requires specifi-
cation of the primary outcome instrument, the expected
difference between the treated and untreated groups, the
pooled standard deviation, the desired statistical power,
whether the hypothesis testing is one- or two-sided and
the significance level (alpha). Over the 37 studies report-
ing sample size calculation, 31 (83 %) and 32 (86 %)
studies reported statistical power and alpha value re-
spectively, but the primary outcome instrument, the ex-
pected difference between groups and whether the test
was one- or two-sided were mentioned in only 17
(46 %), 19 (51 %) and 14 (38 %) studies respectively.
From the 17 studies reporting the primary outcome in-
strument, the Tinnitus Handicap Inventory was the most
popular choice (n = 8). However, the magnitude of the ex-
pected change varied from study to study. It ranged from
6.55 to 20 points, but was also expressed as 50 % of reduc-
tion. Note that the developers of the Tinnitus Handicap
Inventory recommend that a 20-point or greater change is
required to account for test-retest variability [29].
The third quality assessment highlighted that many of
the studies are suboptimal in terms of clearly defining what
end point is the most important with respect to drawing a
conclusion about treatment efficacy. For assessing whether
Fig. 3 Pattern of usage over time for selected primary outcome instruments. Note that the identification of studies categorised as ‘pre-July 2006’
may not be representative as many records relating to this period would have been excluded according to our search criteria
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an intervention has therapeutic benefit to patients, it is
good practice to state a priori one outcome instrument
[30]. Figure 4 illustrates the number of primary outcome
instruments administered in each study. Just over half of all
studies (118/228, 52 %) reported only one primary measure.
However, the remainder reported multiple measures with-
out distinguishing primary from secondary outcomes, with
70 studies (31 %) reporting two or three potential primary
measures, 29 studies (13 %) reporting four or five and 11
studies reporting more than this. Two studies reported 12
measures without distinguishing primary from secondary
outcomes [31, 32].
Exploring the pattern of primary outcomes across tinnitus
subgroups
A final analysis pre-specified in the published protocol
was an exploratory one to address the question about
whether a particular outcome domain (or instrument)
was preferentially selected in trials enrolling a particular
tinnitus subtype [16]. Here we considered tinnitus sever-
ity (as denoted by the authors), hearing loss, depression
and anxiety because these are most relevant for deter-
mining choice of a tailored intervention.
Tinnitus severity
With respect to the primary domains, 96 out of the 505
came from studies that specified a severe tinnitus as an in-
clusion criterion. In those studies, an objective criterion
was defined as some sort of minimum score on a pub-
lished tinnitus questionnaire. For this subgroup compared
to all 228 studies, we expected there would be a greater
proportion of primary domains evaluating the functional
impact of tinnitus, but this was not the case. The pattern
was not noticeably different from the full dataset.
Hearing loss
Forty-seven of the 505 primary domains came from stud-
ies that specified a hearing loss as an inclusion criterion.
Again, only studies were considered where an objective
criterion had been defined and this was typically a mini-
mum hearing level in dB at particular frequencies. Com-
pared to the full dataset reported in Table 3, the
proportion assessing tinnitus distress was slightly lower
(4 % compared to 7 %). We also noted that the only study
to report on a speech-based primary measure was part of
this hearing loss subgroup [33]. Other audiological do-
mains such as loudness and pitch had the same pattern of
usage as the full dataset.
Depression and anxiety
Only one registered clinical trial actively recruited par-
ticipants experiencing a comorbid depressive state [34],
and no studies specified an inclusion criterion for a co-
morbid generalised anxiety. It is not possible, therefore,
to consider any patterns within these subgroups.
Discussion
There is a growing general recognition that insufficient at-
tention has been paid to the outcomes measured in clin-
ical trials [14]. Specifically, for tinnitus these limitations
have been acknowledged in a number of systematic re-
views, especially those published by the Cochrane Centre
[35, 36], and have been highlighted by an international
working party of the Tinnitus Research Initiative [15].
Principal findings
No single outcome was reported in all studies. Instead a
diverse range of outcomes were measured and reported.
There are three key messages from our work.
First, over half of all studies did not adequately describe
the domain for which they were predicting a predominant
therapeutic benefit. In these cases, primary (and second-
ary) outcome domains were either not specified at all or
were unclear. We believe that non-reporting mainly
reflected a poor understanding of how important it is for
individual trials to pre-specify the expected outcome.
When conducting the review, we observed that the head-
ings used within trial registries promote the reporting of
instrument choice, rather than the outcome domain.
Second, there was extremely broad diversity of out-
come instruments. Loudness was the most popular per-
ceptual attribute of tinnitus described at the domain
level, but there was no agreement on how to measure it
and the precise methodology was often under-reported.
Examples of descriptions for loudness matching included
‘matching at 1 kHz’, ‘psychoacoustical measure’, and ‘by
audiometry’. Patient-reported questionnaires relating to
the impact of tinnitus were the most common primary out-
come instruments, but again there was no consensus about
which one should be chosen. The Tinnitus Handicap In-
ventory remains the most popular questionnaire instrument
simply because it is translated into the greatest number of
languages. Certainly, it has limitations for the purpose of
Fig. 4 Number of primary outcome instruments reported across the
228 studies included in the review
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outcome measurement [28]. Worthy of note, we advise
caution if pooling findings from the Tinnitus Handicap In-
ventory in a meta-analysis since it is unclear whether all
translations achieve equivalence with the British original
[37]. In compiling the list of tinnitus-related questionnaires
(Table 4), it was striking how uninformative are the ques-
tionnaire names in helping trialists to choose between
them. All include the word ‘tinnitus’ but rarely qualify that
with a description of which tinnitus-related domains or
constructs are assessed by the tool. Generic names and
terms such as ‘handicap’ and ‘severity’ perpetuate the diffi-
culty that many trialists experience in understanding what
construct(s) a particular questionnaire instrument mea-
sures. For example, the Tinnitus Handicap Inventory [23]
predominantly measures the construct of tinnitus-related
distress, while the Tinnitus Handicap Questionnaire [38]
measures the physical, emotional and social consequences
of tinnitus, as well as hearing ability.
Third, treatment-related outcomes were rarely recorded.
Safety, tolerability, side effects and withdrawals might be
domains that all inform the measurement of adverse
events, but these accounted for less than 2 % of primary
outcome domains and 12 % of secondary outcome do-
mains. Again, non-reporting mainly reflected a poor un-
derstanding of how important it is for individual trials to
investigate and report harms, as well as benefits [39].
Comparison with other studies
Our work provides the first detailed set of information on
the selection and reporting of outcome domains and out-
come instruments in clinical trials of tinnitus. One previ-
ous systematic review examined outcomes of randomised
controlled trials of interventions for adults with tinnitus
[11], but outcome data collection and reporting was re-
stricted to ‘use of validated instruments for assessing tin-
nitus symptoms … any audiometric data … length of
follow-up, and adverse event reporting.’ pp. 2–3, not the
full set of outcomes considered in the present review. Re-
ported findings indicated only that 20 % of studies used a
validated tinnitus instrument, 79 % of studies used audio-
metric measurements, 42 % of studies specified adverse
events, and the median follow-up time was 3 months. No
further details were given and what constitutes a ‘validated
instrument’ was not defined, so comparisons are re-
stricted. Our study findings at least confirm the limited
use of patient-reported questionnaire instruments relating
to the impact of tinnitus. While we find little consistency
across studies in reporting adverse events, our findings
suggest that adverse event reporting is about 5 %, mark-
edly less than the 42 % reported by Plein et al. [11].
Our review identifies limitations in the range of re-
ported outcomes in clinical trials that are reflected more
broadly across the field of audiological research. Here
two reviews have been undertaken to identify outcome
measures used in research on adults with hearing loss.
In the first, Granberg et al. [40] conducted a systematic
review of published articles, including a range of study
designs. The authors found 51 different patient-reported
questionnaire instruments relating to the impact of hear-
ing loss out of the 122 studies included, with only 16 be-
ing used twice or more. Our review confirmed similar
diversity (24 different tinnitus-related questionnaire in-
struments) and lack of consensus (14 used twice or
more). In the second, Barker and et al. [41] conducted a
scoping review to document the range and nature of
outcome measurement in the context of adult auditory
rehabilitation. Like us, they included registered trials and
published studies. The most common outcome domain
was ‘hearing handicap’ which was measured in 23 out of
the 37 studies included, using five different patient-
reported questionnaire instruments. Again, the use of
generic terms such as ‘handicap’ perpetuate the difficulty
that many trialists experience in understanding what
construct(s) are measured by a particular questionnaire
instrument. The frequency of reporting adverse events
was not given by Granberg et al. [40], but Barker et al.
[41] stated that no studies reported on adverse events.
Poor reporting of harms-related data is not restricted to
clinical trials in the hearing sciences [42].
Strengths and limitations of the study
The strengths of our study rest on the inclusion of both
registered (ongoing) clinical trials of tinnitus, as well as
published study findings and on the broad-ranging and
comprehensive evaluation of both the outcome domains
and the outcome instruments used. Several potential
limitations were unavoidable due to limited resources.
These were the use of a pre-defined time window and
the exclusion of non-English language records. While
the search strategy excluded trials that were registered
or published prior to July 2006, it is likely to have in-
cluded trials designed prior to this date. However, there
was insufficient information reported to ascertain this
with any degree of certainty. Whether or not any sys-
tematic bias was introduced by the use of an English-
language restriction is also uncertain, and may not affect
systematic review conclusions [43].
Our study adds new insights to an emerging body of
empirical evidence on outcome reporting within ENT
and audiology trials [40, 41]. Our findings should help to
steer trialists in these disciplines about good reporting
practice, as well as to inform Cochrane and other sys-
tematic reviewers on the choice of outcomes for their
work. Our study leads us to agree with Hoare et al. that
‘To be useful, future studies should … be consistent in
their use of outcome measures’ [35].
The longer-term intention for this work is to develop a
core outcome set that identifies by consensus a minimum
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standard for reporting in clinical trials of tinnitus in adults.
This review makes a specific contribution to that ambi-
tious endeavour by identifying which domains have been
defined in relevant clinical trial designs to date. When de-
veloping a core outcome set, it is important to capture in
the long list of potential outcome domains all those that
need to be considered for inclusion [44]. For that long list
to be truly comprehensive, it is important to capture rele-
vant information that is contained within those studies. A
limitation of the current review concerns those domain def-
initions that were unclear or not specified by their authors.
This is especially important where the domains relate to
patient-reported outcomes of the impact of tinnitus. One
way to address the current gap is to deconstruct the
patient-reported outcome instruments by creating a list of
all questionnaire items, grouping individual items into simi-
lar constructs or domains and then cross-checking them
against the current domain list reported here [44].
Conclusions
We are the first group to conduct a systematic review that
targets the reporting of outcome domains and instruments
in clinical trial designs that evaluate interventions for tin-
nitus. The findings of this review have produced an ex-
tremely rich dataset that has enabled us to address a
number of different primary and secondary questions con-
cerning different aspects of good trial design. Our findings
add important new insights pointing to the lack of aware-
ness and understanding of good trial design in so far as this
relates to outcomes. A general lack of consensus regarding
the choice of outcomes did affect trial design, conduct and
reporting with particular reference to lack of sample size
calculation, and lack of robust interpretation of whether the
intervention was therapeutically beneficial or not.
Our findings emphasise the need to improve trial de-
sign and reporting. A small number of the included
studies in our review acknowledged Consolidated Stan-
dards of Reporting Trials (CONSORT) guidelines for
reporting [45], but this is more the exception than the
rule. Using such guidelines would improve definitions of
all outcome measures including pre-specifying the time
point of primary interest as well as detailed reporting of
any important changes to methods or outcomes after
the trial commenced with reasons for such changes. To
improve reporting, we draw attention to the specialised
CONSORT guidelines for reporting harms-related issues
in a randomised controlled trial [39].
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